Dick Chan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1272875/publications.pdf

Version: 2024-02-01

94 papers	2,958 citations	126708 33 h-index	174990 52 g-index
95 all docs	95 docs citations	95 times ranked	3034 citing authors

#	Article	IF	Citations
1	Randomized controlled trial of the effect of nâ€“3 fatty acid supplementation on the metabolism of apolipoprotein B-100 and chylomicron remnants in men with visceral obesity. American Journal of Clinical Nutrition, 2003, 77, 300-307.	2.2	165
2	Effect of Ezetimibe on Hepatic Fat, Inflammatory Markers, and Apolipoprotein B-100 Kinetics in Insulin-Resistant Obese Subjects on a Weight Loss Diet. Diabetes Care, 2010, 33, 1134-1139.	4.3	145
3	Apolipoprotein B-100 kinetics in visceral obesity: Associations with plasma apolipoprotein C-III concentration. Metabolism: Clinical and Experimental, 2002, 51, 1041-1046.	1.5	129
4	Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics. European Heart Journal, 2018, 39, 2577-2585.	1.0	116
5	Markers of Triglyceride-rich Lipoprotein Remnant Metabolism in Visceral Obesity. Clinical Chemistry, 2002, 48, 278-283.	1.5	109
6	Dyslipidemia in Visceral Obesity. American Journal of Cardiovascular Drugs, 2004, 4, 227-246.	1.0	94
7	Adiponectin and other Adipocytokines as Predictors of Markers of Triglyceride-Rich Lipoprotein Metabolism. Clinical Chemistry, 2005, 51, 578-585.	1.5	93
8	Factorial study of the effect of nâ€“3 fatty acid supplementation and atorvastatin on the kinetics of HDL apolipoproteins A-I and A-II in men with abdominal obesity. American Journal of Clinical Nutrition, 2006, 84, 37-43.	2.2	91
9	Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism. Circulation, 2017, 135, 338-351.	1.6	80
10	Apolipoproteins C-III and A-V as Predictors of Very-Low-Density Lipoprotein Triglyceride and Apolipoprotein B-100 Kinetics. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 590-596.	1.1	72
11	Elevated lipoprotein(a), hypertension and renal insufficiency as predictors of coronary artery disease in patients with genetically confirmed heterozygous familial hypercholesterolemia. International Journal of Cardiology, 2015, 201, 633-638.	0.8	66
12	Plasma Proprotein Convertase Subtilisin/Kexin Type 9: A Marker of LDL Apolipoprotein B-100 Catabolism?. Clinical Chemistry, 2009, 55, 2049-2052.	1.5	63
13	Plasma Apolipoprotein C-III Transport in Centrally Obese Men: Associations with Very Low-Density Lipoprotein Apolipoprotein B and High-Density Lipoprotein Apolipoprotein A-I Metabolism. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 557-564.	1.8	62
14	Very Low Density Lipoprotein Metabolism and Plasma Adiponectin as Predictors of High-Density Lipoprotein Apolipoprotein A-I Kinetics in Obese and Nonobese Men. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 989-997.	1.8	62
15	Dyslipidaemia in the metabolic syndrome and type 2 diabetes: pathogenesis, priorities, pharmacotherapies. Expert Opinion on Pharmacotherapy, 2011, 12, 13-30.	0.9	59
16	Kinetic and Related Determinants of Plasma Triglyceride Concentration in Abdominal Obesity. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 2218-2224.	1.1	58
17	Recent studies of lipoprotein kinetics in the metabolic syndrome and related disorders. Current Opinion in Lipidology, 2006, 17, 28-36.	1.2	53
18	Nonalcoholic Fatty Liver Disease as the Transducer of Hepatic Oversecretion of Very-Low-Density Lipoproteinâ€“Apolipoprotein B-100 in Obesity. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 1043-1050.	1.1	52

#	Article	IF	Citations
19	Plasma Proprotein Convertase Subtilisin Kexin Type 9 as a Predictor of Carotid Atherosclerosis in Asymptomatic Adults. Heart Lung and Circulation, 2016, 25, 520-525.	0.2	50
20	Atorvastatin and Fenofibrate Have Comparable Effects on VLDL-Apolipoprotein C-III Kinetics in Men With the Metabolic Syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 1831-1837.	1.1	49
21	Familial combined hyperlipidemia and hyperlipoprotein(a) as phenotypic mimics of familial hypercholesterolemia: Frequencies, associations and predictions. Journal of Clinical Lipidology, 2016, 10, 1329-1337.e3.	0.6	46
22	PCSK9 Inhibition with alirocumab increases the catabolism of lipoprotein(a) particles in statin-treated patients with elevated lipoprotein(a). Metabolism: Clinical and Experimental, 2020, 107, 154221.	1.5	46
23	Effects of Extended-Release Niacin on the Postprandial Metabolism of Lp(a) and ApoB-100â€“Containing Lipoproteins in Statin-Treated Men With Type 2 Diabetes Mellitus. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 2686-2693.	1.1	45
24	Menopausal Status and Abdominal Obesity Are Significant Determinants of Hepatic Lipid Metabolism in Women. Journal of the American Heart Association, 2015, 4, e002258.	1.6	44
25	Mechanism of Action of a 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor on Apolipoprotein B-100 Kinetics in Visceral Obesity. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 2283-2289.	1.8	43
26	Lipoprotein transport in the metabolic syndrome: methodological aspects of stable isotope kinetic studies. Clinical Science, 2004, 107, 221-232.	1.8	42
27	Lipoprotein transport in the metabolic syndrome: pathophysiological and interventional studies employing stable isotopy and modelling methods. Clinical Science, 2004, 107, 233-249.	1.8	42
28	Effect of atorvastatin and fish oil on plasma high-sensitivity C-reactive protein concentrations in individuals with visceral obesity. Clinical Chemistry, 2002, 48, 877-83.	1.5	42
29	A Comparative Analysis of Phenotypic Predictors of Mutations in Familial Hypercholesterolemia. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1704-1714.	1.8	41
30	Lipoprotein(a) Particle Production as a Determinant of Plasma Lipoprotein(a) Concentration Across Varying Apolipoprotein(a) Isoform Sizes and Background Cholesterolâ€Lowering Therapy. Journal of the American Heart Association, 2019, 8, e011781.	1.6	40
31	Inter-relationships between proprotein convertase subtilisin/kexin typeÂ9, apolipoprotein C-III and plasma apolipoprotein B-48 transport in obese subjects: a stable isotope study in the postprandial state. Clinical Science, 2015, 128, 379-385.	1.8	39
32	Effect of Lipoprotein(a) on the Diagnosis of Familial Hypercholesterolemia: Does It Make a Difference in the Clinic?. Clinical Chemistry, 2019, 65, 1258-1266.	1.5	37
33	Apolipoprotein A-II: Evaluating its significance in dyslipidaemia, insulin resistance, and atherosclerosis. Annals of Medicine, 2012, 44, 313-324.	1.5	35
34	The metabolic and pharmacologic bases for treating atherogenic dyslipidaemia. Best Practice and Research in Clinical Endocrinology and Metabolism, 2014, 28, 369-385.	2.2	32
35	Pathogenesis and Management of the Diabetogenic Effect of Statins: a Role for Adiponectin and Coenzyme Q10?. Current Atherosclerosis Reports, 2015, 17, 472.	2.0	32
36	Comparative aspects of the care of familial hypercholesterolemia in the â€œTen Countries Studyâ€. Journal of Clinical Lipidology, 2019, 13, 287-300.	0.6	32

#	Article	IF	Citations
37	Association of Serum Lipoprotein (a) With the Requirement for a Peripheral Artery Operation and the Incidence of Major Adverse Cardiovascular Events in People With Peripheral Artery Disease. Journal of the American Heart Association, 2020, 9, e015355.	1.6	30
38	Effect of atorvastatin on chylomicron remnant metabolism in visceral obesity: a study employing a new stable isotope breath test. Journal of Lipid Research, 2002, 43, 706-12.	2.0	30
39	Ï‰-3 Fatty Acid Ethyl Esters Diminish Postprandial Lipemia in Familial Hypercholesterolemia. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3732-3739.	1.8	29
40	Plasma Markers of Cholesterol Homeostasis and Apolipoprotein Bâ€100 Kinetics in the Metabolic Syndrome. Obesity, 2003, 11, 591-596.	4.0	27
41	Relationships between cholesterol homoeostasis and triacylglycerol-rich lipoprotein remnant metabolism in the metabolic syndrome. Clinical Science, 2003, 104, 383-388.	1.8	27
42	Effects of atorvastatin and nâˆ’3 fatty acid supplementation on VLDL apolipoprotein C-III kinetics in men with abdominal obesity. American Journal of Clinical Nutrition, 2010, 91, 900-906.	2.2	25
43	Apolipoprotein B-48 as a determinant of endothelial function in obese subjects with type 2 diabetes mellitus: Effect of fenofibrate treatment. Atherosclerosis, 2012, 221, 484-489.	0.4	25
44	Association of Plasma Ceramides and Sphingomyelin With VLDL apoB-100 Fractional Catabolic Rate Before and After Rosuvastatin Treatment. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2497-2501.	1.8	24
45	The Knowns and Unknowns of Contemporary Statin Therapy for Familial Hypercholesterolemia. Current Atherosclerosis Reports, 2020, 22, 64.	2.0	24
46	Postprandial lipoprotein metabolism in familial hypercholesterolemia: thinking outside the box. Metabolism: Clinical and Experimental, 2012, 61, 3-11.	1.5	23
47	Adipose tissue compartments and insulin resistance in overweight-obese Caucasian men. Diabetes Research and Clinical Practice, 2004, 63, 77-85.	1.1	22
48	Apolipoprotein B-100 and ApoA-II Kinetics as Determinants of Cellular Cholesterol Efflux. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E1658-E1666.	1.8	22
49	Markers of triglyceride-rich lipoprotein remnant metabolism in visceral obesity. Clinical Chemistry, 2002, 48, 278-83.	1.5	21
50	Variation in Niemannâ€“Pick C1-like 1 gene as a determinant of apolipoprotein B-100 kinetics and response to statin therapy in centrally obese men. Clinical Endocrinology, 2008, 69, 45-51.	1.2	16
51	Regulatory Effects of Fenofibrate and Atorvastatin on Lipoprotein A-I and Lipoprotein A-I:A-II Kinetics in the Metabolic Syndrome. Diabetes Care, 2009, 32, 2111-2113.	4.3	16
52	Apolipoprotein(a) Kinetics in Statin-Treated Patients With Elevated Plasma Lipoprotein(a) Concentration. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 6247-6255.	1.8	16
53	Origin and therapy for hypertriglyceridaemia in type 2 diabetes. World Journal of Diabetes, 2014, 5, 165.	1.3	16
54	An age-matched computed tomography angiographic study of coronary atherosclerotic plaques in patients with familial hypercholesterolaemia. Atherosclerosis, 2020, 298, 52-57.	0.4	14

#	Article	IF	Citations
55	Gaps in the Care of Familial Hypercholesterolaemia in Australia: First Report From the National Registry. Heart Lung and Circulation, 2021, 30, 372-379.	0.2	14
56	Improving detection and management of familial hypercholesterolaemia in Australian general practice. Heart, 2021, 107, 1213-1219.	1.2	13
57	Transcriptomic therapy for dyslipidemias utilizing nucleic acids targeted at ANGPTL3. Future Cardiology, 2022, 18, 143-153.	0.5	13
58	Angiographic progression of coronary atherosclerosis in patients with familial hypercholesterolaemia treated with non-statin therapy: Impact of a fat-modified diet and a resin. Atherosclerosis, 2016, 252, 82-87.	0.4	12
59	Coronary artery disease and the risk-associated LPA variants, rs3798220 and rs10455872, in patients with suspected familial hypercholesterolaemia. Clinica Chimica Acta, 2020, 510, 211-215.	0.5	11
60	Cascade testing for elevated lipoprotein(a) in relatives of probands with familial hypercholesterolaemia and elevated lipoprotein(a). Atherosclerosis, 2022, 349, 219-226.	0.4	11
61	Familial Hypercholesterolemia and Elevated Lipoprotein(a): Cascade Testing and Other Implications for Contextual Models of Care. Frontiers in Genetics, 2022, 13, 905941.	1.1	11
62	Apolipoprotein A-II and adiponectin as determinants of very low-density lipoprotein apolipoprotein B-100 metabolism in nonobese men. Metabolism: Clinical and Experimental, 2011, 60, 1482-1487.	1.5	10
63	Fractional turnover of apolipoprotein(a) and apolipoprotein B-100 within plasma lipoprotein(a) particles in statin-treated patients with elevated and normal Lp(a) concentration. Metabolism: Clinical and Experimental, 2019, 96, 8-11.	1.5	10
64	New Insights Into the Regulation of Lipoprotein Metabolism by PCSK9: Lessons From Stable Isotope Tracer Studies in Human Subjects. Frontiers in Physiology, 2021, 12, 603910.	1.3	10
65	Triglycerideâ€rich lipoprotein metabolism in women: roles of apoCâ€<scp>II</scp> and apoCâ€<scp>III</scp>. European Journal of Clinical Investigation, 2016, 46, 730-736.	1.7	9
66	A Tale of Two New Targets for Hypertriglyceridaemia: Which Choice of Therapy?. BioDrugs, 2022, 36, 121-135.	2.2	9
67	Cascade testing for elevated lipoprotein(a) in relatives of probands with high lipoprotein(a). American Journal of Preventive Cardiology, 2022, 10, 100343.	1.3	9
68	PCSK9 inhibition with alirocumab decreases plasma lipoprotein(a) concentration by a dual mechanism of action in statinâ€treated patients with very high apolipoprotein(a) concentration. Journal of Internal Medicine, 2022, 291, 870-876.	2.7	8
69	Apolipoprotein B-100 kinetics and static plasma indices of triglyceride-rich lipoprotein metabolism in overweight men. Clinical Biochemistry, 2005, 38, 806-812.	0.8	7
70	Regulation of proprotein convertase subtilisin/kexin type 9: Therapeutical perspectives. Atherosclerosis, 2011, 217, 77-79.	0.4	7
71	A genetic risk score predicts coronary artery disease in familial hypercholesterolaemia: enhancing the precision of risk assessment. Clinical Genetics, 2020, 97, 257-263.	1.0	7
72	Effectiveness of proprotein convertase subtilisin/kexinâ€9 monoclonal antibody treatment on plasma lipoprotein(a) concentrations in patients with elevated lipoprotein(a) attending a clinic. Clinical Cardiology, 2021, 44, 805-813.	0.7	7

#	Article	IF	Citations
73	Unravelling lipoprotein metabolism with stable isotopes: tracing the flow. Metabolism: Clinical and Experimental, 2021, 124, 154887.	1.5	7
74	Lipoprotein kinetics in the metabolic syndrome: pathophysiological and therapeutic lessons from stable isotope studies. Clinical Biochemist Reviews, 2004, 25, 31-48.	3.3	7
75	Effect of a PCSK9 inhibitor and a statin on cholesterol efflux capacity: A limitation of current cholesterolâ€lowering treatments?. European Journal of Clinical Investigation, 2022, , e13766.	1.7	6
76	Dyslipidemia in the metabolic syndrome. Journal of Drug Evaluation, 2004, 2, 3-34.	0.0	5
77	Recent explanatory trials of the mode of action of drug therapies on lipoprotein metabolism. Current Opinion in Lipidology, 2016, 27, 550-556.	1.2	5
78	Lipoprotein(a) in Patients With Type 2 Diabetes and Premature Coronary Artery Disease in the Coronary Care Unit. Heart Lung and Circulation, 2021, 30, 734-740.	0.2	5
79	ApoA-II HDL Catabolism and Its Relationships With the Kinetics of ApoA-I HDL and of VLDL1, in Abdominal Obesity. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 1398-1406.	1.8	4
80	Novel behavioural approaches and implementation science for mitigating genetic risk of cardiovascular disease due to elevated lipoprotein(a). Current Opinion in Endocrinology, Diabetes and Obesity, 2021, 28, 174-180.	1.2	4
81	Atherogenic Dyslipoproteinemia and Management of ASCVD. Journal of the American College of Cardiology, 2020, 75, 2136-2139.	1.2	3
82	Metabolism of lipoprotein(a). Current Opinion in Lipidology, 2020, 31, 163-165.	1.2	3
83	Angiopoietin-like protein 3 inhibitors and contemporary unmet needs in lipid management. Current Opinion in Lipidology, 2021, 32, 210-212.	1.2	3
84	Implications of new clinical practice guidance on familial hypercholesterolaemia for Australian general practitioners. Australian Journal of General Practice, 2021, 50, 616-621.	0.3	3
85	Recent dynamic studies of the metabolism of atherogenic lipoproteins: elucidating the mode of action of new therapies. Current Opinion in Lipidology, 2021, 32, 378-385.	1.2	3
86	Recent advances in the investigation of lipoprotein metabolism using tracer methodology. Clinical Laboratory, 2006, 52, 353-61.	0.2	3
87	Awareness of familial hypercholesterolaemia in Australian primary care: A qualitative descriptive study. Australian Journal of General Practice, 2021, 50, 634-640.	0.3	2
88	Microplastics, cardiometabolic risk, genetics and Alzheimer's disease. Current Opinion in Endocrinology, Diabetes and Obesity, 2022, 29, 85-86.	1.2	2
89	Differences in plasma PLTP activity assays: constant or random error?. Clinical Endocrinology, 2007, 67, 317-317.	1.2	1
90	Effect of Omega-3 Fatty Acid Supplementation on the Postprandial Metabolism of Apolipoprotein(a) in Familial Hypercholesterolemia. Journal of Atherosclerosis and Thrombosis, 2022, , .	0.9	1

#	Article	IF	Citations
91	PANACEA or much a do about nothing: Effect of a statin and ezetimibe on postprandial lipaemia and endothelial function in the metabolic syndrome. Atherosclerosis, 2013, 227, 32-34.	0.4	0
92	More data needed on curcuminoids in hypertriglyceridaemia. Nature Reviews Cardiology, 2014, 11, 123-123.	6.1	0
93	Response by Watts et al to Letter Regarding Article, â€œFactorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolismâ€• Circulation, 2017, 136, 120-121.	1.6	0
94	High Prevalence of Lipid-Related Residual Risk in ACS Patients. Heart Lung and Circulation, 2021, , .	0.2	0